Instrument Inactif

Autres langues Protalex, Inc.

Actions

PRTX

US7436422098

Recherche biotechnologique et médicale

Autres langues

30/11/18	Protalex, Inc. Announces Management Resignations
12/10/18	Protalex Plans To Raise Funds
15/06/18	Protalex, Inc. Announces Data Highlighting Results from European Phase 1b of PRTX-100 in Patients with Immune Thrombocytopenia
12/06/18	Protalex, Inc. Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in Mouse Model of Myasthenia Gravis
09/04/18	Protalex, Inc. Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia
28/02/18	Protalex, Inc. announced that it has received $1.43 million in funding
18/01/18	Protalex Doses First Patient in Final and Highest Dose Cohort of European Phase 1b Study of PRTX-100 in Immune Thrombocytopenia
13/11/17	Protalex Doses First Patient in Fourth Cohort of European Phase 1b Study of PRTX-100 in ITP
26/10/17	Protalex, Inc. Announces Preclinical Data of Haematology Supporting the Potential of PRTX-100 to Treat Immune Thrombocytopenia
29/08/17	Protalex Doses First Patient in Third Cohort of European Phase 1b Study of PRTX-100 in ITP
01/08/17	Protalex, Inc. Announces Completion of Escalating the U.S. Phase 1/2 Study of PRTX-100 in Adults
21/02/17	Protalex, Inc. Provides Update on US and EU Studies of PRTX-100 to Treat Immune Thrombocytopenia
07/07/16	Protalex, Inc. Enters Amendment to Credit Facility
02/05/16	Protalex Inc. Receives Positive Interim Review from Independent Safety Monitoring Committee in its European Phase 1B Study of PRTX-100 to Treat Immune Thrombocytopenia
25/04/16	Protalex Announces Preliminary Findings from Phase I/II Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
29/02/16	Protalex Announces Interim Review of its U.S. Phase 1/2 Study of PRTX-100 for Immune Thrombocytopenia
07/01/16	Protalex, Inc. Announces First Patient Dosed in European Phase Ib Study of PRTX-100 for Immune Thrombocytopenia
05/10/15	Protalex Announces Regulatory Approval to Initiate Phase Ib Trial of PRTX-100 to Treat Immune Thrombocytopenia in France
03/09/15	Protalex, Inc. to Initiate Enrollment of U.S. Phase I/II Trial of PRTX-100 to Treat Immune Thrombocytopenia
31/07/15	Protalex, Inc. Auditor Raises 'Going Concern' Doubt
16/04/15	Protalex Announces Findings from Final Cohort of U.S. Phase 1b Trial of Prtx-100 in Active Rheumatoid Arthritis Patients
12/03/15	Protalex, Inc. Initiates Enrollment of Phase I/Ii Continuation Trial of PRTX-100 in Active Rheumatoid Arthritis Patients
18/11/14	Protalex Inc. Announces Data from Phase 1b Trial of PRTX 100 in Patients with Active Rheumatoid Arthritis
07/11/14	Protalex Inc. Enters New Credit Facility Agreement with Niobe Ventures, LLC
15/05/14	Protalex Announces Results from Cohorts 1-4